## AMENDMENTS TO THE CLAIMS

1 - 7 (Canceled).

8 (Currently Amended). A system according to claim ~~7~~ 32

wherein the adsorption medium is characterized by a Biocompatibility Index of not greater than 14.

9 (Original). A system according to claim 8

wherein the Biocompatibility Index is not greater than 7.

10 – 25 (Canceled)

26 (Currently Amended). A system for treating a physiologic fluid drawn from an individual comprising

draw means for drawing a physiologic fluid from a targeted body region elsewhere than the blood circulatory system,

circulation means for circulation the physiologic fluid outside the individual for treatment,

return means for returning the physiologic fluid to the targeted body region after treatment,

primary treatment means in the circulation means for treating the physiologic fluid according to a primary treatment modality, and

auxiliary treatment means in the circulation means for removing from the physiologic fluid, before, during, or after the primary treatment modality, cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators ~~from the physiologic fluid~~ which can be generated at least in part ~~during~~ as a result of the ~~circulation~~ primary treatment modality.

27 (Original). A system according to claim 26

wherein the physiologic fluid includes peritoneal dialysis solution.

28 (Original). A system according to claim 26

wherein the physiologic fluid includes lymphatic fluid.

29 (Original). A system according to claim 26

wherein the physiologic fluid includes synovial fluid.

30 (Original). A system according to claim 26

wherein the physiologic fluid includes cerebrospinal fluid.

31 (Original). A system according to claim 26

wherein the physiologic fluid includes spinal fluid.

32 (Currently Amended). A system according to claim 26

wherein the auxiliary treatment means ~~for removing~~ includes an adsorption medium to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators.

33 (Original). A system according to claim 32

wherein the adsorption medium comprises a polymeric material.

34 (Original). A system according to claim 33

wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α-methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

35 (Original). A system according to claim 33

wherein the polymeric material comprises particles formed from crosslinked polystyrene type resins having a surface modified to minimize activation of blood complement system.

36 (Original). A system according to claim 33

wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2 hydroxyethyl methacrylate, N vinylpyrrolidine, N vinylcaprolactame and N acrylamide.

37 (Original). A system according to claim 33

wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ solvents.

38 (Currently Amended). A method for treating a physiologic fluid drawn from an individual comprising the steps of

(i) drawing a physiologic fluid from a targeted body region elsewhere than the blood circulatory system,

(ii) circulation the physiologic fluid outside the individual for treatment ~~for return to the targeted body region~~, ~~and~~

(iii) during step (ii), treating the physiologic fluid according to a primary treatment modality,

(iv) during step (ii), removing from the physiologic fluid cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators ~~from the physiologic fluid during the circulation~~ which can be generated at least in part as a result of the primary treatment modality, and

(v) returning the physiologic fluid to the targeted body region after treatment.

39 (Original). A method according to claim 38

wherein the physiologic fluid includes peritoneal dialysis solution.

40 (Original). A method according to claim 38

wherein the physiologic fluid includes lymphatic fluid.

41 (Original). A method according to claim 38

wherein the physiologic fluid includes synovial fluid.

42 (Original). A method according to claim 38

wherein the physiologic fluid includes cerebrospinal fluid.

43 (Original). A method according to claim 38

wherein the physiologic fluid includes spinal fluid.

44 (Currently Amended). A method according to claim 38

wherein ~~the removing~~ step (iv) includes use of an adsorption medium to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators.

45 (Original). A method according to claim 44

wherein the adsorption medium comprises a polymeric material.

46 (Original). A method according to claim 45

wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α-methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

47 (Original). A method according to claim 45

wherein the polymeric material comprises particles formed from crosslinked polystyrene type resins having a surface modified to minimize activation of blood complement system.

48 (Original). A method according to claim 45

wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups

selected from the group of polymers of 2 hydroxyethyl methacrylate, N vinylpyrrolidine, N vinylcaprolactame and N acrylamide.

49 (Original). A method according to claim 45

wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ solvents.

50 - 58 (Canceled).

59 (New). A method according to claim 44

wherein the adsorption medium is characterized by a Biocompatibility Index of not greater than 14.

60 (New). A method according to claim 59

wherein the Biocompatibility Index is not greater than 7.